When PD-1 inhibitors are used, MM patients tend to have a) all-grade irAE-GI (colitis and diarrhea) and irAE-skin (rash and pruritis) than NSCLC patients; b) more irAE-GI (diarrhea), irAE-skin, irAE-endocrine (hypothyroidism), and irAE-musculoskeletal (arthralgia) than RCC patients; c) fewer irAE-lung (pneumonitis and dyspnea) compared to NSCLC and RCC patients d) irAE incidence is later than lung cancer patients (5.2 vs. 2.1 months) (21, 34). This evidence concerns the gene PDCD1 and lung carcinoma.